<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347097</url>
  </required_header>
  <id_info>
    <org_study_id>KY2017-241</org_study_id>
    <nct_id>NCT03347097</nct_id>
  </id_info>
  <brief_title>Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme</brief_title>
  <official_title>The Safety and Efficacy Study of Autologous Tumor-infiltrating T Lymphocyte（TIL）and Transgenic Modified TIL Cells Adoptive Therapies for Patients With Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Cell Therapy Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, the investigators want to evaluate safety and efficacy of cell therapy based on&#xD;
      Tumor-infiltrating T Lymphocyte (TIL）in glioblastoma. Here, we also constructed a transgenic&#xD;
      modified TIL cells, stablely express a high-level full-length PD1 antibody (PD1-TIL cells),&#xD;
      which can transduce signals to activate T cells and result in tumor killing. In this study,&#xD;
      we design two group patients treated with TIL cells and PD1-TIL cells respectively to&#xD;
      determine the safety and efficacy of autologous TILs or genetically modified TILs in patients&#xD;
      with glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events related to TIL and PD1-TIL cells infusion</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Responses Rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>TIL cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 days after the end of chemotherapy or radiotherapy，the 300ml TIL cells ( TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD1-TIL cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 days after the end of chemotherapy or radiotherapy，the 300ml PD1-TIL cells ( PD1-TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIL</intervention_name>
    <arm_group_label>TIL cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD1-TIL</intervention_name>
    <arm_group_label>PD1-TIL cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Recurrent patients with histologically confirmed brain glioblastoma multiforme.&#xD;
&#xD;
          2. Patients with maximum safe resection of the tumor (≥95%) confirmed with contrast MR or&#xD;
             CT within 72 hours after surgery.&#xD;
&#xD;
          3. Age from 18 to 70 years.&#xD;
&#xD;
          4. Karnofsky performance score ≥ 60.&#xD;
&#xD;
          5. Adequate organ function within 14 days of study registration including the following:&#xD;
             Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count, (ANC) ≥&#xD;
             1.0×10^9/L, platelets ≥100×10^9/L; hemoglobin ≥ 9 g/dL. Hepatic: bilirubin ≤1.3 mg/dL&#xD;
             or 0-22 mmol/L, aspartate transaminase (AST) and alanine transaminase (ALT) &lt; 3×upper&#xD;
             limit of normal (ULN). Renal: Normal serum Creatinine for age (below) or creatinine&#xD;
             clearance &gt;60 ml/min/1.73 m2. Electrocardiogram: normal.&#xD;
&#xD;
          6. Written informed consent must be obtained from all patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast-feeding patients. Pregnancy testing will be performed on all&#xD;
             menstruating females within 14 days of study enrollment.&#xD;
&#xD;
             Patients with uncontrolled intercurrent illness including, but not limited to ongoing&#xD;
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             or psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements.&#xD;
&#xD;
          2. Patients with history of immune system abnormalities such as hyperimmunity (e.g.,&#xD;
             autoimmune diseases) and hypoimmunity (e.g., myelodysplastic disorders, marrow&#xD;
             failures, AIDS, ongoing pregnancy, transplant immuno-suppression), or medication of&#xD;
             cortisol.&#xD;
&#xD;
          3. Patients with any conditions that could potentially alter immune function (e.g., AIDS,&#xD;
             multiple sclerosis, diabetes, renal failure).&#xD;
&#xD;
        Patients currently received any other investigational agents.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huashan hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Yu Yao, MD</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>TIL</keyword>
  <keyword>PD1-TIL</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

